The idea of building the APIRA pharmaceutical factory in 2017 came to our mind from the country’s twenty-year roadmap to achieve maximum independence, especially in strategic industries such as drug supply.
To achieve our goal, we focused on less-targeted, knowledge-based sectors, which ensure profitable outcomes for our stockholders. In order to have better communication with countries in the geopolitical Middle East region, we decided to dedicate more than 7,000 square meters to the factory in the food and pharmaceutical section of the Industrial City of Kaveh Special Economic Zone.
The APIRA slogan, infinite innovation, is only attainable through more stringent standards compared to those of the local ones. Therefore, we follow the highest international standards and organize a well-oriented research and development team for the factory, which has already attracted the attention of knowledgeable counterparts in the pharmaceutical industry.
It is expected that soon after raising the scheduled funds, different departments of the factory will launch in the first phase, followed by completing the value chain. Our valuable achievement would result in several benefits, as follows:
Saving Foreign Exchange:
Currently, more than one billion dollars is dedicated to the import of medicines, semi-finished formulations, and active pharmaceutical ingredients. Despite all the efforts made by the government and private sectors to reduce this dependence, many companies prefer to import medicines and raw pharmaceuticals from countries such as India and China, which offer similar products at more competitive prices. Thanks to the application of state-of-the-art technology, we decided to produce similar products at competitive prices to reduce our country’s dependency on imports by 20 million dollars.
Job Creation:
Entrepreneurship, followed by job creation, is a prime mission of manufacturing companies. Our country currently has many efficient and knowledgeable human resources, which should be wisely incorporated into the industry. At its maximum capacity, APIRA leads to the direct employment of more than 200 individuals.
Reasonable Profitability:
Increased international sanctions against our country, followed by governmental support for domestic products during the last few years, have led to a significant rise in the profitability of pharmaceutical companies. There is no doubt that after lifting sanctions and normalization of relations, international investors will rush to increase their market share with more competitive prices. In such cases, only companies that apply the newest technology, ideas, and features could provide competitive prices and establish reasonable profitability for their stockholders
In the opposite photos, you can see the progress of building walls stage of the APIRA factory construction project.
